Q&A with INmune’s Dr RJ Tesi: is TNF the key to treating the Covid-19 cytokine storm?
California-based INmune decided to leverage its TNF platform and launch a Phase II trial of its selective inhibitor of soluble TNF (sTNF), Quellor, in hospitalised Covid-19 patients. Quellor differs from the existing TNF inhibitors on the market, which are prescribed for inflammatory conditions ranging from rheumatoid arthritis, inflammatory bowel disease and psoriasis, because it only […]
Q&A with INmune’s Dr RJ Tesi: is TNF the key to treating the Covid-19 cytokine storm? Read More »